Baxter International, Inc.

889 articles with Baxter International, Inc.

• Baxter Declares Quarterly Dividend - Nov 16, 2021

  11/16/2021

  Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products.

• Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility

  11/11/2021

  Baxter International Inc., a global leader in sterile medication production and delivery, announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany.

• Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference

  11/2/2021

  Baxter International Inc., a leading global medical products company, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021.

• Baxter Reports Third-Quarter 2021 Results

  10/28/2021

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021.

• Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury

  10/21/2021

  Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test.

• Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference

  10/13/2021

  Baxter to Present at Credit Suisse 30 th Annual Virtual Healthcare Conference

• Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress

  10/5/2021

  Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress

• Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation

  9/23/2021

  Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).

• Baxter to Present at UBS Genomics 2.0 and MedTech Innovations Summit

  7/29/2021

  Baxter International Inc., a leading global medical products company, will present at the UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 in Laguna Beach, Calif.

• Baxter Reports Second-Quarter 2021 Results

  7/29/2021

  Baxter International Inc., a leading global medical products company, reported results for the second quarter of 2021.

• CryoLife Announces Sale of PerClot to Baxter

  7/29/2021

  CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc., for up to $60.8 million in cash.

• Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

  7/29/2021

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront.

• Baxter Supports Analysis Demonstrating Clinical and Economic Benefits of Effective Intraoperative Blood Management for Surgical Patients

  7/15/2021

  Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, recognizes the findings of a large retrospective observational analysis published in the Journal of Medical Economics.

• Baxter Declares Quarterly Dividend - July 12, 2021

  7/12/2021

  Baxter International Inc., a leading global medical products company, announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock.

• Baxter Launches New 2030 Corporate Responsibility Commitment to Advance Environmental, Social and Governance Priorities

  7/8/2021

  Baxter International Inc. today released its 2020 Corporate Responsibility Report .

• Baxter Announces $1.2 Million in New Scholarships and Grant Funding to Support Students Pursuing Health and Sciences at Historically Black Colleges and Universities in the United States

  6/29/2021

  Baxter International Inc. announced today the introduction of three scholarship and grant programs to support Black students pursuing health and science degrees and ultimately help expand the pipeline of Black healthcare professionals.

• Baxter to Host Second-Quarter 2021 Financial Results Conference Call for Investors

  6/15/2021

  Baxter International Inc. will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time.

• Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations

  6/8/2021

  Baxter Presents Data at 58 th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations.

• Baxter Launches the Sharesource Analytics 1.0 Digital Health Module to Enhance Clinical Management of Home Dialysis Patients

  6/2/2021

  Next generation digital health module uniquely designed to keep patients on home dialysis by helping identify potential therapy complications Sharesource Analytics will further enhance healthcare professionals’ ability to keep peritoneal dialysis patients safer at home during the COVID-19 pandemic

• Baxter Launches PrisMax 2 System to Advance Critical Care Delivery for Patients and Hospitals

  5/25/2021

  Baxter International Inc., a global leader in acute care, announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform.